Glenmark upbeat on Indian crofelemer study in acute diarrhoea
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals has reported positive results from an exploratory Phase II proof-of-concept study of Napo Pharmaceuticals' anti-secretory gastrointestinal agent, crofelemer, which was carried out in India in adult patients with acute watery diarrhoea.